Literature DB >> 18791365

Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients.

John B Holcomb1, Charles E Wade, Joel E Michalek, Gary B Chisholm, Lee Ann Zarzabal, Martin A Schreiber, Ernest A Gonzalez, Gregory J Pomper, Jeremy G Perkins, Phillip C Spinella, Kari L Williams, Myung S Park.   

Abstract

OBJECTIVE: To determine the effect of blood component ratios in massive transfusion (MT), we hypothesized that increased use of plasma and platelet to red blood cell (RBC) ratios would result in decreased early hemorrhagic death and this benefit would be sustained over the ensuing hospitalization. SUMMARY BACKGROUND DATA: Civilian guidelines for massive transfusion (MT > or =10 units of RBC in 24 hours) have typically recommend a 1:3 ratio of plasma:RBC, whereas optimal platelet:RBC ratios are unknown. Conversely, military data shows that a plasma:RBC ratio approaching 1:1 improves long term outcomes in MT combat casualties. There is little consensus on optimal platelet transfusions in either civilian or military practice. At present, the optimal combinations of plasma, platelet, and RBCs for MT in civilian patients is unclear.
METHODS: Records of 467 MT trauma patients transported from the scene to 16 level 1 trauma centers between July 2005 and June 2006 were reviewed. One patient who died within 30 minutes of admission was excluded. Based on high and low plasma and platelet to RBC ratios, 4 groups were analyzed.
RESULTS: Among 466 MT patients, survival varied by center from 41% to 74%. Mean injury severity score varied by center from 22 to 40; the average of the center means was 33. The plasma:RBC ratio ranged from 0 to 2.89 (mean +/- SD: 0.56 +/- 0.35) and the platelets:RBC ratio ranged from 0 to 2.5 (0.55 +/- 0.50). Plasma and platelet to RBC ratios and injury severity score were predictors of death at 6 hours, 24 hours, and 30 days in multivariate logistic models. Thirty-day survival was increased in patients with high plasma:RBC ratio (> or =1:2) relative to those with low plasma:RBC ratio (<1:2) (low: 40.4% vs. high: 59.6%, P < 0.01). Similarly, 30-day survival was increased in patients with high platelet:RBC ratio (> or =1:2) relative to those with low platelet:RBC ratio (<1:2) (low: 40.1% vs. high: 59.9%, P < 0.01). The combination of high plasma and high platelet to RBC ratios were associated with decreased truncal hemorrhage, increased 6-hour, 24-hour, and 30-day survival, and increased intensive care unit, ventilator, and hospital-free days (P < 0.05), with no change in multiple organ failure deaths. Statistical modeling indicated that a clinical guideline with mean plasma:RBC ratio equal to 1:1 would encompass 98% of patients within the optimal 1:2 ratio.
CONCLUSIONS: Current transfusion practices and survival rates of MT patients vary widely among trauma centers. Conventional MT guidelines may underestimate the optimal plasma and platelet to RBC ratios. Survival in civilian MT patients is associated with increased plasma and platelet ratios. Massive transfusion practice guidelines should aim for a 1:1:1 ratio of plasma:platelets:RBCs.

Entities:  

Mesh:

Year:  2008        PMID: 18791365     DOI: 10.1097/SLA.0b013e318185a9ad

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  233 in total

Review 1.  Blood component therapy in trauma guided with the utilization of the perfusionist and thromboelastography.

Authors:  Mark Walsh; Scott G Thomas; Janet C Howard; Edward Evans; Kirk Guyer; Andrew Medvecz; Andrew Swearingen; Rudolph M Navari; Victoria Ploplis; Francis J Castellino
Journal:  J Extra Corpor Technol       Date:  2011-09

2.  Creation, implementation, and maturation of a massive transfusion protocol for the exsanguinating trauma patient.

Authors:  Timothy C Nunez; Pampee P Young; John B Holcomb; Bryan A Cotton
Journal:  J Trauma       Date:  2010-06

3.  Aged plasma transfusion increases mortality in a rat model of uncontrolled hemorrhage.

Authors:  Phillip A Letourneau; Madonna McManus; Kendell Sowards; Weiwei Wang; Yao-wei Wang; Nena Matijevic; Shibani Pati; Charles E Wade; John B Holcomb
Journal:  J Trauma       Date:  2011-11

4.  Clotting factor deficiency in early trauma-associated coagulopathy.

Authors:  Sandro B Rizoli; Sandro Scarpelini; Jeannie Callum; Bartolomeu Nascimento; Kenneth G Mann; Ruxandra Pinto; Jan Jansen; Homer C Tien
Journal:  J Trauma       Date:  2011-11

5.  Computational modelling of lung injury: is there potential for benefit?

Authors:  Daniel J R Harvey; Jonathan G Hardman
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-01-27       Impact factor: 6.237

6.  Cause and timing of death in massively transfused trauma patients.

Authors:  Michael W Cripps; Matthew E Kutcher; Aaron Daley; Ryan C McCreery; Molly D Greenberg; Leslie M Cachola; Brittney J Redick; Mary F Nelson; Mitchell Jay Cohen
Journal:  J Trauma Acute Care Surg       Date:  2013-08       Impact factor: 3.313

7.  The impact of increased plasma ratios in massively transfused trauma patients: a prospective analysis.

Authors:  E Bui; K Inaba; A Ebadat; E Karamanos; S Byerly; O Okoye; I Shulman; P Rhee; D Demetriades
Journal:  Eur J Trauma Emerg Surg       Date:  2015-09-11       Impact factor: 3.693

8.  [S3 guideline on treatment of polytrauma/severe injuries. Trauma room care].

Authors:  S Lendemans; S Ruchholtz
Journal:  Unfallchirurg       Date:  2012-01       Impact factor: 1.000

9.  Coordination and management of multicenter clinical studies in trauma: Experience from the PRospective Observational Multicenter Major Trauma Transfusion (PROMMTT) Study.

Authors:  Mohammad H Rahbar; Erin E Fox; Deborah J del Junco; Bryan A Cotton; Jeanette M Podbielski; Nena Matijevic; Mitchell J Cohen; Martin A Schreiber; Jiajie Zhang; Parsa Mirhaji; Sarah J Duran; Robert J Reynolds; Ruby Benjamin-Garner; John B Holcomb
Journal:  Resuscitation       Date:  2011-10-12       Impact factor: 5.262

10.  Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial.

Authors:  Jessica C Cardenas; Xu Zhang; Erin E Fox; Bryan A Cotton; John R Hess; Martin A Schreiber; Charles E Wade; John B Holcomb
Journal:  Blood Adv       Date:  2018-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.